Alzahrani, Ahmad H.
Skytte, Mads J.
Samkani, Amirsalar
Thomsen, Mads N.
Astrup, Arne
Ritz, Christian
Chabanova, Elizaveta
Frystyk, Jan
Holst, Jens J.
Thomsen, Henrik S.
Madsbad, Sten
Haugaard, Steen B.
Krarup, Thure
Larsen, Thomas Meinert
Magkos, Faidon http://orcid.org/0000-0002-1312-7364
Clinical trials referenced in this document:
Documents that mention this clinical trial
Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet
https://doi.org/10.1007/s00394-021-02605-0
Funding for this research was provided by:
The Novo Nordisk Foundation Center for Basic Metabolic Research
Arla Food for Health
University of Copenhagen; the Department of Clinical Medicine
Aarhus University
The Department of Nutrition, Exercise and Sports and the Department of Biomedical Sciences, University of Copenhagen
The Copenhagen University Hospital, Bispebjerg
The University of Jeddah, Jeddah, Saudi Arabia
Article History
Received: 3 September 2020
Accepted: 2 June 2021
First Online: 8 June 2021
Declarations
:
: Arne Astrup is currently employed by The Novo Nordisk Foundation to establish a National Centre for Healthy Weight, and is member of the advisory board or serves as consultant for: Gelesis, USA; Groupe Éthique et Santé, France; and Weight Watchers, USA. He is co-owner and member of the board of the Danish consultancy companies Dentacom Aps, Flaxslim ApS, and Personalized Weight Management Research Consortium ApS; and co-inventor of a number of patents owned by the University of Copenhagen in accordance with Danish law. Thomas Meinert Larsen is advisor for the “Sense” diet program. The remaining authors have no conflicts of interest to declare.